Literature DB >> 6831055

Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration.

B G Durie, L A Young, S E Salmon.   

Abstract

Ninety-seven patients with multiple myeloma evaluated serially had both a tritiated thymidine labeling index of bone marrow plasma cells (LI%) and in vitro myeloma stem cell culture performed. Thirty-three patients with myeloma colony growth had in vitro drug sensitivity testing carried out, 18 having in addition in vitro thymidine suicide determinations. The LI% and the likelihood of in vitro myeloma colony growth were highly correlated: the higher the LI%, the more likely was colony or cluster growth (p less than 0.001). The tritiated thymidine suicide of myeloma stem cells was usually very high. There was excellent correlation between in vitro and in vivo drug sensitivity. Both pretreatment drug resistance and selective sensitivity (e.g., interferon, bisantrene, methotrexate, vinblastine) at the time of relapse were accurately detected and correlated well with survival duration (p = 0.01 Wilcoxan). Although LI% and in vitro sensitivity were clearly independent variables, a high LI% (greater than 3%) plus in vitro resistance were associated with a subsequent survival duration of less than 6 mo. The studies allowed dissection of the complex interrelationship between cell kinetics and drug sensitivity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831055

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Stimulation of growth of human malignant lymphoma and lymphoid leukemia cells in vitro.

Authors:  E S Strobel; K J Bross; R Mertelsmann; F Herrmann
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

2.  Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study.

Authors:  B G Durie; J Crowley; C A Coltman; R A Chapman; S P Balcerzk; J D Bonnet; D A Lipschitz; R L Stephens; B D Cheson
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

Review 3.  Human B cell colony assays.

Authors:  J C Kluin-Nelemans; R Willemze
Journal:  Blut       Date:  1987-10

Review 4.  Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development.

Authors:  D D von Hoff
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

5.  Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.

Authors:  Zachary J Walker; Michael J VanWyngarden; Brett M Stevens; Diana Abbott; Andrew Hammes; Christophe Langouët-Astrie; Clayton A Smith; Brent E Palmer; Peter A Forsberg; Tomer M Mark; Craig T Jordan; Daniel W Sherbenou
Journal:  Blood Adv       Date:  2020-04-28

6.  Cell kinetics and in vitro clonogenicity of primary colorectal cancer: clinicopathological relationships and the implications for chemotherapy.

Authors:  G A Trotter; G R Morgan; A J Cooper; N Kirkham; J M Whitehouse; I Taylor
Journal:  Gut       Date:  1985-03       Impact factor: 23.059

7.  Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern.

Authors:  H M Lokhorst; S E Boom; B J Bast; P J Peters; T F Tedder; J Gerdes; E Petersen; R E Ballieux
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

8.  Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma.

Authors:  D G Thomas; J L Darling; E A Paul; T J Mott; J N Godlee; J S Tobias; L G Capra; C D Collins; C Mooney; T Bozek
Journal:  Br J Cancer       Date:  1985-04       Impact factor: 7.640

9.  The human tumour cloning assay in the management of breast cancer patients.

Authors:  C Dittrich; R Jakesz; F Wrba; L Havelec; O Haas; J Spona; H Holzner; R Kolb; K Moser
Journal:  Br J Cancer       Date:  1985-08       Impact factor: 7.640

Review 10.  Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.

Authors:  Manfred Volm; Thomas Efferth
Journal:  Front Oncol       Date:  2015-12-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.